Shareholders endorse Grifols’ growth strategy

- Victor Grifols, President and CEO, informed shareholders of the company’s most recent corporate operations, focusing in particular on the definitive agreement to purchase Novartis’ transfusional diagnostics unit.

- Shareholders ratified all items on the agenda, including the renewal of the delegation of authority to the Board of Directors to perform a possible stock split, and to apply for the NASDAQ listing of voting shares. Both items had already been approved in December 2012 for a period of 1 year.

**Barcelona, December 17, 2013:** The shareholders of Grifols (MCE:GRF, MCE:GRF.P and NASDAQ:GRFS), the world’s third-largest producer of plasma-derived biological medicines, demonstrated their support to the group’s strategy of growth through acquisitions at the Extraordinary General Meeting held today on second call.

454 shareholders, accounting for 149,904,502 Class A shares and representing 70.35% of the company’s voting shares were represented at the Extraordinary General Meeting. The shareholders expressed their confidence in the company’s management and its future, endorsing by majority all the items on the agenda, with 82.88% of votes delegated to the Board of Directors.

Víctor Grifols, President and CEO of the company, informed shareholders of the company’s definitive agreement to purchase Novartis’ transfusional diagnostics unit for 1,675 million dollars (1,240 million euros), announced on November 11.

The shareholders gave majority support to the renewal, for a further year, of the decision to delegate powers to the Board of Directors to perform a possible stock split of the company’s shares, and to apply for the listing of class A shares on the NASDAQ. Both items of the agenda had already been approved in December 2012 for a period of 1 year.

**Latest corporate transactions: Acquisition of Novartis’ transfusional diagnostics unit**

The definitive agreement to purchase Novartis’ transfusional diagnostics unit, subject to approval by competition regulators, is part of Grifols’ growth strategy of complementing its range of plasma protein therapies with other diagnostic products and services. This will increase Grifols’ global potential enabling the company to
provide integrated solutions for blood and plasma donor centers, from donation through to transfusion.

Following the acquisition, Grifols’ Diagnostic division will account for over 20% of the company’s sales volume compared to the current figure of 4%, with an estimated turnover close to 1,000 million US dollars.

The assets acquired include *in vitro* diagnostic products and technology for transfusion medicine and immunology, a manufacturing plant in the USA, and commercial offices in USA, Switzerland and Hong Kong. The funding for the operation is fully committed, in the form of a bridge loan for 1,500 million dollars, fully subscribed in equal parts by Nomura, Morgan Stanley, and BBVA.

Grifols has also acquired a 21.30% holding in TiGenix, a biotechnological company, for 12 million euros. This operation is aligned with Grifols’ strategy of participating in biotech projects and companies to support innovative initiatives in fields such as advanced therapies and personalized medicine. TiGenix is listed on NYSE Euronext Brussels, and is dedicated to the research and development of stem cells derived from adipose tissue.

**Renewal for a further year of the delegation of authority to the Board of Directors**

Shareholders approved by majority the renewal of the delegation of powers to the Board of Directors for a further year. This authorization would allow members of the Board to consider a possible stock split of Class A and Class B (non-voting) shares, and to apply for the listing of Class A shares on the NASDAQ.

The renewal does not necessarily mean that either of these steps – both of which have been possible since December 2012 – will be undertaken. The approved conditions for the potential stock split if undertaken were set at a proportion of 2 new shares for each 1 old share, reducing their nominal value and increasing the number of shares (to be multiplied by two). The nominal value of the company’s total share capital would not change.

The company’s current share capital totals 119.5 million euros, represented by 213,064,899 ordinary shares (Class A) with a nominal value of 0.50 euros per share, and 130,712,555 non-voting shares (Class B) with a nominal value of 0.10 euros each.

Grifols ordinary shares (Class A) are listed on the Spanish Continuous Market, and are a component of the Ibex-35 (GRF). Grifols non-voting shares (Class B) are listed on the Continuous Market (GRF.P) and on the NASDAQ (GRFS) via ADRs (American Depositary Receipts).
About Grifols
Grifols is a global company with over 70 years of experience of contributing to improving people’s health and well-being by promoting plasma protein therapies, clinical diagnosis technology and pharmaceutical preparations for hospital use.

It is currently the world’s third-largest producer of plasma-based biological medicines, with a presence in over 100 countries, and is the leading supplier of plasma, with 150 donor centers in the United States. Grifols is committed to improving access to plasma protein therapies through the continuous improvement and expansion of its manufacturing facilities and exploring new therapeutic potential for plasma proteins. The company, which has its head office in Barcelona, Spain, employs over 11,000 members of staff.

In 2012, its sales exceeded 2,620 million euros. Ordinary Grifols shares (Class A) are listed on the Spanish Continuous Market, where they form part of the Ibex-35 (GRF), while its non-voting shares (Class B) are also listed on the Continuous Market (GRF.P) and on the NASDAQ (GRFS) via ADRs (American Depositary Receipts). For more information, visit www.grifols.com

LEGAL NOTICE
The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. The information, opinions and statements in this document with regard to pro forma figures have not been audited or verified by independent third parties, and the company therefore in no way guarantees the impartiality, precision, integrity or accuracy of this information or these figures, opinion and statements. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Act 24/1988, of 28 July, on Stock Exchanges; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation.